Edesa Biotech, Inc. operates as a clinical-stage biopharmaceutical company. The Company offers drugs for the treatment of dermatological and gastrointestinal diseases including alternatives to topical steroids. Edesa Biotech serves patients in the United States and Canada.

Current Report (Form 8-K | Period ending 2024-10-30)

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edesa Biotech (EDSA US)

Current Report (Form 8-K | Period ending 2024-10-30)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-10-03)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-09)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)